Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2156-2162

  LaPlante, Kerry L ^a,d   Leonard, Steven N ^a   Andes, David R ^c   Craig, William A ^c   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPTOMYCIN; DOXYCYCLINE; LINCOSAMIDE; LINEZOLID; MIKAMYCIN B; VANCOMYCIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIOSTASIS; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; COLONY COUNT, MICROBIAL; COMMUNITY-ACQUIRED INFECTIONS; CULTURE MEDIA; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; MICE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN;

EID: 44449128060     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01046-07     Document Type: Article

References (34)

1. Aeschlimann, J. R., M. J. Zervos, and M. J. Rybak. 1998. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 42:2710-2717.
2. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
3. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
4. Alsarra, I. A., M. S. Al-Said, K. I. Al-Khamis, E. M. Niazy, V. M. El-Sayed, K. A. Al-Rashood, M. J. Al-Vamani, and S. A. Al-Balla. 2004. Comparative bioavailability study of doxycycline hyclate (equivalent to 100 mg doxycycline) capsules (doxycin vs vibramycin) for bioequivalence evaluation in healthy adult volunteers. Int. J. Clin. Pharmacol. Ther. 42:373-377.
5. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
6. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
7. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
8. Centers for Disease Control and Prevention. 2006, posting date. Community-associated MRSA information for clinicians. www.cdc.gov/ncidod/dhqp/ ar_mrsa_ca_clinicians.html.
9. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. JAMA 282:1123-1125.
10. Centers for Disease Control and Prevention. 2002. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison: Mississippi, 2000. JAMA 287:181-182.
11. Centers for Disease Control and Prevention. 2001. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison: Mississippi, 2000. MMWR Morb. Mortal. Wkly. Rep. 50:919-922.
12. Clinical and Laboratory Standards Institute. 2004. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard. CLSI, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2004. Supplemental tables M100-S13, 15th ed. CLSI, Wayne, PA.
14. Christiansen, J. C., W. A. Craig, S. Kiem, and D. R. Andes. 2002. Impact of neutrophils on pharmacodynamic activity of clindamycin (CLINDA) and doxycycline (DOXY) against Streptococcus pneumoniae, abstr. A-1267. Abstr. 42nd Intersci. Conf. Antimicrob. Agents. Chemother. American Society for Microbiology, Washington, DC.
15. Coyle, E. A., R. Cha, and M. J. Rybak. 2003. Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin A release. Antimicrob. Agents Chemother. 47:1752-1755.
16. Craig, W. A., D. Andes, K. L. LaPlante, and M. J. Rybak. 2005. In vivo activity of clindamycin (CLIN), daptomycin (DAP), doxycycline (DOXY), and linezolid (LND) against clindamycin inducible-resistance (CIR) community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in a murine thigh infection model, abstr. A-428. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. Craig, W. A., S. Kiem, and D. R. Andes. 2002. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides, and clindamycin, abstr. A-1267, p. 14. 42nd Intersci. Conf. Antimicrob. Agents Chemother.
18. Dvorchik, B., and D. Damphousse. 2004. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J. Clin. Pharmacol. 44:612-620.
19. Farrell, D. J., I. Morrissey, S. Bakker, L. Morris, S. Buckridge, and D. Felmingham. 2004. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J. Clin. Microbiol. 42:764-768.
20. Fiebelkorn, K. R., S. A. Crawford, M. L. McElmeel, and J. H. Jorgensen. 2003. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J. Clin. Microbiol. 41:4740-4744.
21. Frank, A. L., J. F. Marcinak, P. D. Mangat, J. T. Tjhio, S. Kelkar, P. C. Schreckenberger, and J. P. Quinn. 2002. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. 21:530-534.
22. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.
23. LaPlante, K. L., and M. J. Rybak. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.
24. LaPlante, K. L., M. J. Rybak, M. Amjad, and G. W. Kaatz. 2007. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy 27:3-10.
25. Lewis, R. E., M. E. Klepser, E. J. Ernst, B. C. Lund, D. J. Biedenbach, and R. N. Jones. 1999. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrob. Agents Chemother. 43:2005-2009.
26. Mazur, D., B. S. Schug, G. Evers, V. Larsimont, H. Fieger-Buschges, W. Gimbel, A. Keilbach-Bermann, and H. H. Blume. 1999. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int. J. Clin. Pharmacol. Ther. 37:386-392.
27. Peng, G. W., R. P. Stryd, S. Murata, M. Igarashi, K. Chiba, H. Aoyama, M. Aoyama, T. Zenki, and N. Ozawa. 1999. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J. Pharm. Biomed. Anal. 20:65-73.
28. Rybak, M. J., and K. L. LaPlante. 2005. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 25:74-85.
29. Saano, V., P. Paronen, and P. Peura. 1990. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets-comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:471-474.
30. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
31. Siberry, G. K., T. Tekle, K. Carroll, and J. Dick. 2003. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. 37:1257-1260.
32. Slatter, J. G., D. J. Stalker, K. L. Feenstra, I. R. Welshman, J. B. Bruss, J. P. Sams, M. G. Johnson, P. E. Sanders, M. J. Hauer, P. E. Fagerness, R. P. Stryd, G. W. Peng, and E. M. Shobe. 2001. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
33. Wise, R., T. Gee, J. M. Andrews, B. Dvorchik, and G. Marshall. 2002. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33.
34. Zhang, K., J. A. McClure, S. Elsayed, T. Louie, and J. M. Conly. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5026-5033.